Cogent Biosciences, Inc. 8-K

What Happened
Cogent Biosciences, Inc. (COGT) filed a Current Report on Form 8-K on February 17, 2026 (Accession No. 0001193125-26-053131) announcing that it issued a press release reporting its financial results for the year ended December 31, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference in the filing.

Key Details

• Filing date: February 17, 2026.
• Reporting period: year ended December 31, 2025.
• Exhibit included: Press release (Exhibit 99.1) announcing the results; Inline XBRL cover page included as Exhibit 104.
• Reported under Form 8-K Item 2.02 (Results of Operations and Financial Condition).

Why It Matters
This 8-K signals that Cogent has publicly reported its latest annual financial results (earnings, revenue and related metrics). Retail investors should review the attached press release for the company’s reported revenue, profit/loss, and any management commentary or outlook; also watch for the company’s subsequent 10-K or earnings presentation for audited and detailed financial statements and disclosures.